Panacea Index Logo

Command Palette

Search for a command to run...

Current and future treatments of secondary osteoporosis.

Best practice & research. Clinical endocrinology & metabolism
December 1, 2014
Raquel Soriano et al. (4 authors)
Journal ArticleReviewHuman Study
Extracted Claims (5)
InterventionDirectionEndpointPopulationDosageImpactClaim #
calcium and vitamin D supplementation
neutral
secondary osteoporosis
-
-
generally advised
#1
specific antiosteoporosis medications
neutral
high risk of fracture
-
-
should be prescribed
#2
bisphosphonates
neutral
secondary osteoporosis
-
-
most widely used
#3
denosumab
neutral
secondary osteoporosis
-
-
assessed
#4
teriparatide
neutral
secondary osteoporosis
-
-
assessed
#5
Abstract

Osteoporosis is commonly associated with menopause and ageing. It can, however, also be caused by diseases, lifestyle, genetic diseases, drug therapies and other therapeutic interventions. In cases of secondary osteoporosis, a common rule is the management of the underlying condition. Healthy habits and calcium and vitamin D supplementation are also generally advised. In cases of high risk of fracture, specific antiosteoporosis medications should be prescribed. For most conditions, the available evidence is limited. Special attention should be paid to possible contraindications of drugs used for the treatment of postmenopausal or senile osteoporosis. Bisphosphonates are the most widely used drugs in secondary osteoporosis, and denosumab or teriparatide have been also assessed in some cases. Important research is needed to develop more tailored strategies, specific to the peculiarities of the different types of secondary osteoporosis.

Medical Subject Headings (MeSH)
Antibodies, Monoclonal, HumanizedBone Density Conservation AgentsDenosumabDiphosphonatesHumansOsteoporosisTeriparatide
Study Links
Citation Metrics
Total Citations16
Citations/Year1.5
Relative Citation Ratio0.67
NIH Percentile35.8%
Research Impact Scores
APT Score0.50
Related Supplements